Up to 80% of people encounter severe adverse events in their lives (De Vries & Olff, 2009). Most people will be resilient or quickly recover from negative symptoms, but a significant proportion will develop posttraumatic stress disorder (PTSD) leading to a lifetime prevalence of PTSD in about 7% (De Vries & Olff, 2009; Kessler et al., 2005). These events precipitate not only PTSD but also major depression, anxiety disorders, addiction, physical health problems, and other trauma-related disorders.

Abstract
Background
Pharmacological treatment is widely used for post-traumatic stress disorder (PTSD) despite questions over its efficacy.
Aims
To determine the efficacy of all types of pharmacotherapy, as monotherapy, in reducing symptoms of PTSD, and to assess acceptability.
Method
A systematic review and meta-analysis of randomised controlled trials was undertaken; 51 studies were included.
Results

Abstract
Background: Posttraumatic stress disorder (PTSD) develops in approximately 20% of people exposed to a traumatic event, and studies have shown that cognitive-behavioral therapy (CBT) is effective as a treatment for chronic PTSD. It has also been shown to prevent PTSD when delivered early after a traumatic event. However, studies have shown that uptake of early treatment is generally low, and therefore, the need to provide interventions through other mediums has been identified. The use of technology may overcome barriers to treatment.

Background: The assessment of therapeutic adherence and competence is often neglected in psychotherapy research, particularly in children and adolescents; however, both variables are crucial for the interpretation of treatment effects.

Objective: Our aim was to develop, adapt, and pilot two scales to assess therapeutic adherence and competence in a recent innovative program, Developmentally Adapted Cognitive Processing Therapy (D-CPT), for adolescents suffering from posttraumatic stress disorder (PTSD) after childhood abuse.